Renosen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.00 Cr
as on 16-11-2024
- Satisfied Charges ₹ 3.00 Cr
as on 16-11-2024
- Revenue -49.52%
(FY 2023)
- Profit -65.99%
(FY 2023)
- Ebitda -59.61%
(FY 2023)
- Net Worth 21.10%
(FY 2023)
- Total Assets 42.73%
(FY 2023)
About Renosen Pharmaceuticals
The Corporate was formerly known as Senores Lifesciences Private Limited. The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹10.00 Cr. The company has closed loans amounting to ₹3.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Hemant Modi, Anar Shah, and Swapnil Shah serve as directors at the Company.
- CIN/LLPIN
U51909GJ2019PTC108258
- Company No.
108258
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Renosen Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hemant Modi  | Director | 01-Mar-2021 | Current |
| Anar Shah | Director | 22-May-2019 | Current |
| Swapnil Shah | Director | 22-May-2019 | Current |
Financial Performance and Corporate Structure Insights of Renosen Pharmaceuticals.
Renosen Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 49.52% decrease. The company also saw a substantial fall in profitability, with a 65.99% decrease in profit. The company's net worth Soared by an impressive increase of 21.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Renosen Pharmaceuticals?
In 2023, Renosen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Relius Lifesciences Private LimitedActive 8 years 28 daysAnar Shah and Swapnil Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Jun 2021 | ₹10.00 Cr | Open |
Others Creation Date: 26 Mar 2021 | ₹3.00 Cr | Satisfied |
How Many Employees Work at Renosen Pharmaceuticals?
Unlock and access historical data on people associated with Renosen Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Renosen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renosen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
